HRP20191857T1 - Inhibitori replikacije virusa - Google Patents
Inhibitori replikacije virusa Download PDFInfo
- Publication number
- HRP20191857T1 HRP20191857T1 HRP20191857TT HRP20191857T HRP20191857T1 HR P20191857 T1 HRP20191857 T1 HR P20191857T1 HR P20191857T T HRP20191857T T HR P20191857TT HR P20191857 T HRP20191857 T HR P20191857T HR P20191857 T1 HRP20191857 T1 HR P20191857T1
- Authority
- HR
- Croatia
- Prior art keywords
- 6alkyl
- group
- compound
- aryl
- formula
- Prior art date
Links
- 229940123627 Viral replication inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 150000001923 cyclic compounds Chemical class 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 229940126062 Compound A Drugs 0.000 claims 3
- 206010054261 Flavivirus infection Diseases 0.000 claims 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 3
- -1 heteroC1-6alkyl Chemical group 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (17)
1. Spoj formule (B);
naznačen time što je
- skupina
odabrana od
pri čemu valovita crta (
) označava točku vezanja na karbonil glavne formule (B); pri čemu je navedeni dio supstituiran s jednim ili dva Z1;
- ciklički spoj B je odabran od
i
pri čemu valovita crta (
) označava točku vezanja na ugljikov atom glavne formule (B), i pri čemu su prikazani cikli supstituirani s jednim, dva ili tri Z1a;
- R1 je odabran od C3-7cikloalkila, arila, i heterocikla;
i pri čemu su navedeni C3-7cikloalkil, aril, i heterocikal, supstituirani s jednim, dva ili tri Z1b;
- R2 je vodik;
- svaki Z1, Z1a, i Z1b, je neovisno odabran iz niza koji sadrži halogen, hidroksil, -OZ2, -O-C(=O)Z3, =O, -S(=O)2Z3, -S(=O)2NZ4Z5, trifluorometil, trifluorometoksi, -NZ4Z5, - NZ4C(=O)Z2, -NZ4C(=O)-OZ2, cijano, -C(=O)Z3, - C(=O)OZ2, -C(=O)NZ4Z5, C1-6alkil, heteroC1-6alkil, aril, heterocikal, i heterocikal-C1-6alkil; i pri čemu navedeni C1-6alkil, heteroC1-6alkil, aril, heterocikal, i heterocikal-C1-6alkil, su proizvoljno supstituirani s jednim, dva ili tri supstituenta odabrana iz niza koji čine hidroksil, =O, halogen, trifluorometil, -OCF3, -O-C(O)Me, cijano, nitro, -C(O)OH, -C(O)OC1-6alkil, - NH2, -NHCH3, -N(CH3)2, -NH-C(=O)O-C1-4alkil, -S(O)2C1-4alkil, i -O-C1-6alkil;
- svaki Z2 je neovisno odabran iz niza koji čine C1-6alkil, aril, heterocikal, i heterocikal-C1-6alkil; pri čemu navedeni C1-6alkil, aril, heterocikal, i heterocikal-C1-6alkil, su proizvoljno supstituirani s jednim, dva ili tri supstituenta odabrana iz niza koji čine hidroksil, =O, halogen, trifluorometil, difluorometil, -O-C1-6alkil, -OCF3, -S(=O)2C1-4alkil, cijano, -C(=O)OH, - C(=O)O-C1-4alkil, -NH2, -N(CH3)2, pirolidinil, piperidinil, i piperazinil;
- svaki Z3 je neovisno odabran iz skupine koju čine hidroksil, C1-6alkil, aril, i heterocikal;
pri čemu navedeni C1-6alkil, aril, i heterocikal su proizvoljno supstituirani s jednim, dva ili tri supstituenta odabrana iz niza koji čine C1-6alkil i -N(CH3)2;
- svaki Z4 i Z5 je neovisno odabran iz niza koji čine vodik, C1-6alkil, aril, C3-7cikloalkil, i heterocikal;
i stereoizomeri ili tautomeri, solvati, naročito njihove farmaceutski prihvatljive soli; pri čemu izraz "heterocikal" označava zasićeni, nezasićeni ili aromatski prstenski sustav od 3 do 18 atoma koji uključuje barem jedan N, O, S ili P.
2. Spoj s formulom (B) prema zahtjevu 1, naznačen time što
- svaki Z1, Z1a, i Z1b, je neovisno odabran iz skupine koja sadrži halogen, hidroksil, -OZ2, -O-C(=O)Z3, =O, -S(=O)2Z3, -S(=O)2NZ4Z5, trifluorometil, trifluorometoksi, -NZ4Z5,-NZ4C(=O)Z2, -NZ4C(=O)-OZ2, cijano, -C(=O)Z3, - C(=O)OZ2, -C(=O)NZ4Z5, C1-6alkil, heteroC1-6alkil, aril, heterocikal, i heterocikal-C1-6alkil;
i pri čemu navedeni C1-6alkil, aril, i heterocikal su proizvoljno supstituirani s jednim, dva ili tri supstituenta odabrana iz niza koji čine hidroksil, =O, -O-C(O)Me, cijano, -C(O)OH,-C(O)OC1-6alkil, -NH2, -NHCH3, -N(CH3)2, -NH- C(=O)O-C1-4alkil, -S(O)2C1-4alkil, i -O-C1-6alkil;
- svaki Z je neovisno odabran od C1-6alkil, aril, i heterocikal-C1-6alkil;
pri čemu navedeni C1-6alkil, i aril, su proizvoljno supstituirani s jednim, dva ili tri supstituenta odabrana iz niza koji čine hidroksil, halogen, difluorometil, -O- C1-6alkil, -S(=O)2C1-4alkil, -C(=O)OH, -C(=O)O-C1-4alkil, -NH2, i -N(CH3)2, pirolidinil, piperidinil, i piperazinil;
- svaki Z3 je neovisno odabran iz niza koji čine hidroksil, C1-6alkil, i heterocikal;
pri čemu su navedeni C1-6alkil i heterocikal proizvoljno supstituirani s jednim, dva ili tri supstituenta odabrana iz niza koji čine C1-6alkil i -N(CH3)2;
- svaki Z4 i Z5 je neovisno odabran iz niza koji čine vodik, C1-6alkil, i C3-7cikloalkil;
i stereoizomeri ili tautomeri, solvati, naročito njihove farmaceutski prihvatljive soli.
3. Spoj prema bilo kojem od zahtjeva 1-2, naznačen time što spoj ima strukturu s formulom (D),
pri čemu
- skupina
ciklički spoj B, R1 , i R2 su kako je definirano u bilo kojem od zahtjeva 1-2.
4. Spoj s formulom (D) prema zahtjevu 3, naznačen time što
- skupina
je odabrana od
pri čemu je navedeni dio supstituiran s jednim ili dva Z1;
- ciklički spoj B je odabran od
i
pri čemu valovita crta (
) označava točku vezanja na ugljikov atom glavne formule (D), i pri čemu su prikazani cikli supstituirani s jednim, dva ili tri Z1a;
- R1 je dio odabran od
koji dio je supstituiran s jednim, dva ili tri Z1b;
- Z1b je odabran iz skupine koja sadrži halogen, hidroksil, -OZ2, =O, -S(=O)2Z3, - S(=O)2NZ4Z5, trifluorometil, trifluorometoksi, -NZ4Z5, - NZ4C(=O)Z2, cijano, -C(=O)Z3, - C(=O)OZ2, -C(=O)NZ4Z5, C1-6alkil, aril, i heterocikal;
i pri čemu su navedeni C1-6alkil, aril, i heterocikal proizvoljno supstituirani s jednim, dva ili tri supstituenta odabrana iz niza koji čine hidroksil, =O, -O- C(O)Me, cijano, -C(O)OH, -NHCH3, -N(CH3)2, -S(O)2C1-4alkil, i -O-C1-6alkil;
- R2 je vodik;
- svaki Z1, i Z1a, je neovisno odabran iz skupine koja sadrži halogen, hidroksil,
- OZ2, -O-C(=O)Z3, =O, -S(=O)2Z3, -S(=O)2NZ4Z5, trifluorometil, trifluorometoksi, -NZ4Z5, - NZ4C(=O)Z2, -NZ4C(=O)-OZ2, cijano, -C(=O)Z3, - C(=O)OZ2, -C(=O)NZ4Z5, C1-6alkil, heteroC1-6alkil, aril, heterocikal, i heterocikal-C1-6alkil;
pri čemu su navedeni C1-6alkil, aril, i heterocikal proizvoljno supstituirani s jednim, dva ili tri supstituenta odabrana iz niza koji čine hidroksil, =O, -O- C(O)Me, cijano, -C(O)OH, -C(O)OC1-6alkil, -NH2, -NHCH3, -N(CH3)2, -NH- C(=O)O-C1-4alkil, -S(O)2C1-4alkil, i -O-C1-6alkil;
- Z2 je neovisno odabran od C1-6alkil, aril, i heterocikal-C1-6alkil;
pri čemu su navedeni C1-6alkil, i aril, proizvoljno supstituirani s jednim, dva ili tri supstituenta odabrana iz niza koji čine hidroksil, halogen, difluorometil, -O- C1-6alkil, -S(=O)2C1-4alkil, -C(=O)OH, -C(=O)O-C1-4alkil, -NH2, -N(CH3)2, pirolidinil, piperidinil, i piperazinil;
- Z3 je neovisno odabran od hidroksil, C1-6alkil, i heterocikal;
pri čemu su navedeni C1-6alkil i heterocikal proizvoljno supstituirani s jednim, dva ili tri supstituenta odabrana iz niza koji čine C1-6alkil i -N(CH3)2;
- svaki Z4 i Z5 je neovisno odabran od vodik, C1-6alkil, i C3-7cikloalkil.
5. Spoj prema bilo kojem od zahtjeva 1-4, naznačen time što spoj ima strukturu s formulom (G),
pri čemu ciklički spoj B, R1, R2, i Z1, su kako je definirano u bilo kojem od zahtjeva 1-4, R4 je vodik, i X1 je N ili CH, i n je odabran od 1; i 2.
6. Spoj prema bilo kojem od zahtjeva 1-4, naznačen time što spoj ima strukturu s formulom (H),
pri čemu
- ciklički spoj B, svaki Z1 neovisno, i svaki Z1b neovisno, su kako je definirano u bilo kojem od zahtjeva 1-4;
- m je odabran od 1, 2, i 3;
- n je odabran od 1 i 2;
i
pri čemu X2 je NH i X1 je CH ili N, ili
X2 je S i X1 je CH, ili
X2 je O i X1 je N.
7. Spoj prema bilo kojem od zahtjeva 1-4, naznačen time što spoj ima strukturu s formulom (I),
pri čemu
- svaki Z1 neovisno, i svaki Z1b neovisno, su kako je definirano u bilo kojem od zahtjeva 1-4;
- ciklički spoj B je kako je definirano u zahtjevu 1, pri čemu prikazani cikli su supstituirani sa halogenom, C1-4alkilom, ili C1-4alkoksi;
- n je odabran od 1, i 2; i
- m je odabran od 1, 2, i 3.
8. Spoj prema bilo kojem od zahtjeva 1-2, naznačen time što skupina
je
9. Spoj prema bilo kojem od zahtjeva 1-4, naznačen time što spoj ima strukturu s formulom (F1)
i biciklički dio odabran je od
10. Spoj prema bilo kojem od zahtjeva 1-9, naznačen time što je ugljikov atom supstituiran s cikličkim spojem B u R konfiguraciji.
11. Spoj prema bilo kojem od zahtjeva 1-9, naznačen time što je ugljikov atom supstituiran s cikličkim spojem B u S konfiguraciji.
12. Farmaceutski pripravak naznačen time što sadrži farmaceutski prihvatljiv nosač, te kao aktivni sastojak učinkovitu količinu spoja prema bilo kojem od zahtjeva 1-11 ili njegovu farmaceutski prihvatljivu sol.
13. Postupak za pripravu spoja prema bilo kojem od zahtjeva 1-11 naznačen time što sadrži korak
- reakcije spoja formule (X1) s aminom R1R2NH u odgovarajućem otapalu, pri čemu ciklički spoj A odgovara skupini
s formulom (B) kako je definirano u zahtjevu 1, ciklički spoj B, R1, i R2 imaju značenje prema bilo kojem od zahtjeva 1-9, i LG je odlazeća skupina poznata stručnjaku u stanju tehnike, poželjno odabrana između klora, broma, te joda; ili
- reakcije imina formule (X2) s aldehidom formule (X3) u prisutnosti katalizatora i odgovarajućeg otapala, čime se dobiva spoj formule (A1), pri čemu ciklički spoj A s formulom
ciklički spoj B, i R1, imaju značenje prema bilo kojem od zahtjeva 1-9, i pod uvjetom da u cikličkom spoju A s formulama (X3) i (A1), ugljikov atom veže se na karbonil.
14. Spoj prema bilo kojem od zahtjeva 1-11, naznačen time što je za uporabu kao lijek.
15. Spoj prema bilo kojem od zahtjeva 1-11, naznačen time što je za uporabu za prevenciju ili liječenje flavivirusne infekcije kod životinje, sisavca ili čovjeka.
16. Spoj prema zahtjevu 15 naznačen time što je za uporabu u postupku liječenja ili sprječavanja Flavivirusnih infekcija kod ljudi davanjem učinkovite količine spoja prema bilo kojem od zahtjeva 1-11, ili njegove farmaceutski prihvatljive soli, proizvoljno u kombinaciji s jednim ili više drugih lijekova, pacijentu kojem je to potrebno.
17. Spoj za uporabu prema zahtjevu 15 ili 16, naznačen time što Flavivirusna infekcija je infekcija Denga virusom ili virusom žute groznice.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161626410P | 2011-09-26 | 2011-09-26 | |
GBGB1116559.4A GB201116559D0 (en) | 2011-09-26 | 2011-09-26 | Novel viral replication inhibitors |
EP12775463.8A EP2760831B1 (en) | 2011-09-26 | 2012-09-26 | Viral replication inhibitors |
PCT/EP2012/069007 WO2013045516A1 (en) | 2011-09-26 | 2012-09-26 | Viral replication inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191857T1 true HRP20191857T1 (hr) | 2019-12-27 |
Family
ID=44993373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191857TT HRP20191857T1 (hr) | 2011-09-26 | 2019-10-15 | Inhibitori replikacije virusa |
Country Status (34)
Country | Link |
---|---|
US (3) | US10550123B2 (hr) |
EP (2) | EP3617192A1 (hr) |
JP (2) | JP6266521B2 (hr) |
KR (2) | KR102204695B1 (hr) |
CN (2) | CN108440370B (hr) |
AP (1) | AP2014070535A0 (hr) |
AU (3) | AU2012314498B2 (hr) |
BR (1) | BR112014007134B1 (hr) |
CA (1) | CA2848604C (hr) |
CL (2) | CL2014000732A1 (hr) |
CO (1) | CO7010824A2 (hr) |
CR (1) | CR20140147A (hr) |
CY (1) | CY1122291T1 (hr) |
DK (1) | DK2760831T3 (hr) |
EA (1) | EA032477B1 (hr) |
EC (1) | ECSP14013315A (hr) |
ES (1) | ES2753966T3 (hr) |
GB (1) | GB201116559D0 (hr) |
GT (1) | GT201400053A (hr) |
HR (1) | HRP20191857T1 (hr) |
HU (1) | HUE046540T2 (hr) |
IL (2) | IL231492B (hr) |
LT (1) | LT2760831T (hr) |
ME (1) | ME03605B (hr) |
MX (1) | MX355722B (hr) |
MY (1) | MY182771A (hr) |
PE (1) | PE20141280A1 (hr) |
PL (1) | PL2760831T3 (hr) |
PT (1) | PT2760831T (hr) |
RS (1) | RS59404B1 (hr) |
SG (2) | SG11201400927WA (hr) |
SI (1) | SI2760831T1 (hr) |
UA (2) | UA125790C2 (hr) |
WO (1) | WO2013045516A1 (hr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
EP3381899B1 (en) | 2010-04-22 | 2021-01-06 | Vertex Pharmaceuticals Incorporated | Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds |
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
BR112016023422A8 (pt) | 2014-04-15 | 2021-07-20 | Vertex Pharma | dispersão seca por spray, composição farmacêutica e seus usos, kit e comprimido |
TWI681951B (zh) * | 2014-10-01 | 2020-01-11 | 美商健生醫藥公司 | 作為登革熱病毒複製抑制劑之單-或二-取代的吲哚衍生物 |
AU2015326920A1 (en) * | 2014-10-01 | 2017-03-02 | Janssen Pharmaceuticals, Inc. | Mono- or di-substituted indoles as dengue viral replication inhibitors |
CN105503763B (zh) | 2014-10-17 | 2020-11-03 | 上海中科康润新材料科技有限公司 | 聚烯烃油催化剂及其应用 |
JOP20150335B1 (ar) * | 2015-01-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
EP3286172B1 (en) | 2015-04-23 | 2019-06-12 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
JOP20160086B1 (ar) * | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) * | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JO3633B1 (ar) * | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
CR20180495A (es) * | 2016-03-31 | 2018-12-06 | Univ Leuven Kath | Deribados de indol sustituidos como inhibidores de replicación viral del dengue |
MA44498A (fr) * | 2016-03-31 | 2019-02-06 | Janssen Pharmaceuticals Inc | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue |
WO2017167952A1 (en) * | 2016-04-01 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indole compound derivatives as dengue viral replication inhibitors |
JOP20170069B1 (ar) * | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
CN108473510B (zh) | 2016-04-28 | 2021-10-29 | 豪夫迈·罗氏有限公司 | 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法 |
TWI753037B (zh) | 2016-10-26 | 2022-01-21 | 美商星座製藥公司 | Lsd1抑制劑及其用途 |
JOP20180026A1 (ar) * | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180025B1 (ar) * | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
EP3630724B1 (en) * | 2017-05-22 | 2021-04-28 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
BR112019024195A2 (pt) | 2017-05-22 | 2020-06-23 | Janssen Pharmaceuticals, Inc. | Composto e composição farmacêutica de derivados de indolina substituídos como inibidores da replicação viral da dengue |
CA3091342A1 (en) | 2018-02-16 | 2019-08-22 | Constellation Pharmaceuticals, Inc. | Susbstituted aryl and heteroaryl acetamide derivatives and pharmaceutical compositions thereof useful as p300/cbp hat_inhibitors |
WO2019161157A1 (en) | 2018-02-16 | 2019-08-22 | Constellation Pharmceuticals, Inc. | P300/cbp hat inhibitors |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
AU2001239791A1 (en) * | 2000-02-17 | 2001-08-27 | Du Pont Pharmaceuticals Company | Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production |
GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
AU2002364566B2 (en) | 2001-12-12 | 2009-03-26 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating HSP90 binding activity |
GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
AU2005228894B9 (en) | 2004-03-30 | 2011-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
UA91677C2 (ru) * | 2004-03-30 | 2010-08-25 | Интермюн, Инк. | Макроциклические соединения как ингибиторы вирусной репликации |
CN101084005A (zh) | 2004-12-23 | 2007-12-05 | 诺瓦提斯公司 | 用于黄病毒科治疗的化合物 |
WO2006076529A1 (en) | 2005-01-14 | 2006-07-20 | Genelabs Technologies, Inc. | Indole derivatives for treating viral infections |
US20060194835A1 (en) | 2005-02-09 | 2006-08-31 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
DE102005028845A1 (de) * | 2005-06-22 | 2006-12-28 | Sanofi-Aventis Deutschland Gmbh | Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
WO2007017093A1 (en) | 2005-08-04 | 2007-02-15 | Bayer Healthcare Ag | Substituted 2-benzyloxy-benzoic acid amide derivatives |
EP1922306A2 (en) | 2005-09-02 | 2008-05-21 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009015067A2 (en) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
CN102056483A (zh) | 2008-06-03 | 2011-05-11 | 西佳技术公司 | 用于治疗或预防登革病毒感染的小分子抑制剂 |
US8543331B2 (en) * | 2008-07-03 | 2013-09-24 | Hewlett-Packard Development Company, L.P. | Apparatus, and associated method, for planning and displaying a route path |
US8143259B2 (en) * | 2008-08-19 | 2012-03-27 | Janssen Pharmaceutica, Nv | Cold menthol receptor antagonists |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
CN102656160A (zh) * | 2009-07-16 | 2012-09-05 | 顶点制药公司 | 用于治疗或预防黄病毒感染的苯并咪唑类似物 |
EP2507249B1 (en) | 2009-09-09 | 2015-11-11 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
PE20121522A1 (es) | 2010-01-15 | 2012-11-26 | Gilead Sciences Inc | Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae |
GB201116559D0 (en) * | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
KR102290189B1 (ko) | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 카르복스아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도 |
LT3099687T (lt) | 2014-01-31 | 2018-09-10 | Bristol-Myers Squibb Company | Makrociklai su heterociklinėmis p2' grupėmis kaip faktoriaus xia inhibitoriai |
NO2721243T3 (hr) | 2014-10-01 | 2018-10-20 | ||
AU2015326920A1 (en) | 2014-10-01 | 2017-03-02 | Janssen Pharmaceuticals, Inc. | Mono- or di-substituted indoles as dengue viral replication inhibitors |
TWI681951B (zh) | 2014-10-01 | 2020-01-11 | 美商健生醫藥公司 | 作為登革熱病毒複製抑制劑之單-或二-取代的吲哚衍生物 |
JOP20150335B1 (ar) | 2015-01-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
AU2016350868B2 (en) | 2015-11-03 | 2022-03-31 | Zoetis Services Llc | Sol-gel polymer composites and uses thereof |
CR20180495A (es) | 2016-03-31 | 2018-12-06 | Univ Leuven Kath | Deribados de indol sustituidos como inhibidores de replicación viral del dengue |
MA44498A (fr) | 2016-03-31 | 2019-02-06 | Janssen Pharmaceuticals Inc | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue |
JP6788683B2 (ja) | 2016-03-31 | 2020-11-25 | 武田薬品工業株式会社 | 複素環化合物 |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JP2019513370A (ja) | 2016-04-01 | 2019-05-30 | カイト ファーマ インコーポレイテッドKite Pha | キメラ受容体及びその使用方法 |
BR112018068851B1 (pt) | 2016-04-01 | 2022-11-22 | Basf Se | Composto de fórmula i, composição, métodos de combate ou controle de pragas invertebradas e de proteção de plantas, semente revestida e uso de pelo menos um composto |
IL303785A (en) | 2016-04-01 | 2023-08-01 | Kite Pharma Inc | Chimeric antigen and T cell receptors and methods of use |
MX2018011992A (es) | 2016-04-01 | 2019-01-24 | Signal Pharm Llc | Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos. |
WO2017167952A1 (en) | 2016-04-01 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indole compound derivatives as dengue viral replication inhibitors |
SG10201911963VA (en) | 2016-04-01 | 2020-02-27 | Amgen Inc | Chimeric receptors to flt3 and methods of use thereof |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
BR112019024195A2 (pt) | 2017-05-22 | 2020-06-23 | Janssen Pharmaceuticals, Inc. | Composto e composição farmacêutica de derivados de indolina substituídos como inibidores da replicação viral da dengue |
EP3630724B1 (en) | 2017-05-22 | 2021-04-28 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
-
2011
- 2011-09-26 GB GBGB1116559.4A patent/GB201116559D0/en not_active Ceased
-
2012
- 2012-09-26 MY MYPI2014000873A patent/MY182771A/en unknown
- 2012-09-26 SG SG11201400927WA patent/SG11201400927WA/en unknown
- 2012-09-26 EA EA201490654A patent/EA032477B1/ru unknown
- 2012-09-26 US US14/346,777 patent/US10550123B2/en active Active
- 2012-09-26 UA UAA201708276A patent/UA125790C2/uk unknown
- 2012-09-26 JP JP2014531279A patent/JP6266521B2/ja active Active
- 2012-09-26 PL PL12775463T patent/PL2760831T3/pl unknown
- 2012-09-26 PT PT127754638T patent/PT2760831T/pt unknown
- 2012-09-26 SG SG10201705974PA patent/SG10201705974PA/en unknown
- 2012-09-26 AU AU2012314498A patent/AU2012314498B2/en active Active
- 2012-09-26 CA CA2848604A patent/CA2848604C/en active Active
- 2012-09-26 KR KR1020197020675A patent/KR102204695B1/ko active IP Right Grant
- 2012-09-26 ES ES12775463T patent/ES2753966T3/es active Active
- 2012-09-26 MX MX2014003585A patent/MX355722B/es active IP Right Grant
- 2012-09-26 AP AP2014007535A patent/AP2014070535A0/xx unknown
- 2012-09-26 BR BR112014007134-9A patent/BR112014007134B1/pt active IP Right Grant
- 2012-09-26 CN CN201810458919.3A patent/CN108440370B/zh active Active
- 2012-09-26 WO PCT/EP2012/069007 patent/WO2013045516A1/en active Application Filing
- 2012-09-26 HU HUE12775463A patent/HUE046540T2/hu unknown
- 2012-09-26 SI SI201231674T patent/SI2760831T1/sl unknown
- 2012-09-26 DK DK12775463.8T patent/DK2760831T3/da active
- 2012-09-26 CN CN201280057716.4A patent/CN104024223B/zh active Active
- 2012-09-26 RS RSP20191312 patent/RS59404B1/sr unknown
- 2012-09-26 LT LT12775463T patent/LT2760831T/lt unknown
- 2012-09-26 EP EP19183201.3A patent/EP3617192A1/en active Pending
- 2012-09-26 PE PE2014000413A patent/PE20141280A1/es active IP Right Grant
- 2012-09-26 EP EP12775463.8A patent/EP2760831B1/en active Active
- 2012-09-26 ME MEP-2019-294A patent/ME03605B/me unknown
- 2012-09-26 UA UAA201404302A patent/UA115537C2/uk unknown
- 2012-09-26 KR KR1020147010538A patent/KR102081444B1/ko active IP Right Grant
-
2014
- 2014-03-12 IL IL231492A patent/IL231492B/en active IP Right Grant
- 2014-03-25 CL CL2014000732A patent/CL2014000732A1/es unknown
- 2014-03-26 GT GT201400053A patent/GT201400053A/es unknown
- 2014-04-01 CR CR20140147A patent/CR20140147A/es unknown
- 2014-04-16 EC ECSP14013315 patent/ECSP14013315A/es unknown
- 2014-04-28 CO CO14089597A patent/CO7010824A2/es unknown
-
2016
- 2016-06-17 CL CL2016001580A patent/CL2016001580A1/es unknown
-
2017
- 2017-09-01 AU AU2017221865A patent/AU2017221865B2/en active Active
- 2017-12-20 JP JP2017243354A patent/JP6906437B2/ja active Active
-
2019
- 2019-07-18 US US16/515,272 patent/US11279704B2/en active Active
- 2019-07-30 IL IL268366A patent/IL268366B2/en unknown
- 2019-08-23 AU AU2019219850A patent/AU2019219850B2/en active Active
- 2019-10-15 HR HRP20191857TT patent/HRP20191857T1/hr unknown
- 2019-10-21 CY CY20191101094T patent/CY1122291T1/el unknown
-
2021
- 2021-11-30 US US17/538,532 patent/US20220106321A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191857T1 (hr) | Inhibitori replikacije virusa | |
HRP20210038T1 (hr) | Pirolopirimidini za uporabu u infekciji virusom gripe | |
HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
BR112016023679A2 (pt) | derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos | |
CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
HRP20180081T1 (hr) | Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
JP2016530259A5 (hr) | ||
HRP20211223T1 (hr) | Heterociklički indoli za upotrebu kod infekcije virusom influence | |
BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
ECSP11011560A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
ES2670878T3 (es) | Cianometilpirazol carboxamidas como inhibidores de la Janus quinasa | |
JP2016506962A5 (hr) | ||
EA201390888A1 (ru) | Бензимидазоловые ингибиторы респираторно-синцитиального вируса | |
EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
JP2014508804A5 (hr) | ||
BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda | |
SI3009426T1 (en) | 4-alkynyl imidazole derivatives and a drug containing it as an active ingredient | |
ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
RU2016144076A (ru) | Сильнодействующие и селективные ингибиторы вируса гепатита с | |
AR065297A1 (es) | Formulaciones biodisponibles de compuestos heterociclicos | |
JP2016515550A5 (hr) | ||
RU2014131017A (ru) | Хиназолиноновые производные в качестве ингибиторов hcv | |
RU2010151143A (ru) | Замещенные хиназолины |